Detalles de la búsqueda
1.
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Blood
; 141(14): 1666-1674, 2023 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564045
2.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34269818
3.
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.
Eur J Haematol
; 112(4): 547-553, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38116695
4.
The Beaker phenomenon and the genomic transformation of northwest Europe.
Nature
; 555(7695): 190-196, 2018 03 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29466337
5.
Erratum: The Beaker phenomenon and the genomic transformation of northwest Europe.
Nature
; 555(7697): 543, 2018 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-29565364
6.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37269857
7.
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Br J Haematol
; 201(5): 845-850, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36895158
8.
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis.
Br J Haematol
; 201(4): 682-689, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36822820
9.
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Br J Haematol
; 201(2): 267-279, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36541152
10.
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
J Oncol Pharm Pract
; 29(5): 1172-1177, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36067063
11.
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell response.
Br J Haematol
; 197(3): 293-301, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35064676
12.
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
Br J Haematol
; 196(4): 892-901, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34761389
13.
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.
Blood
; 136(25): 2881-2892, 2020 12 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33113551
14.
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Blood
; 136(9): 1091-1104, 2020 08 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32438407
15.
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Blood
; 136(26): 3033-3040, 2020 12 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33367546
16.
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.
Haematologica
; 107(1): 231-242, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33297668
17.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33428632
18.
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Br J Haematol
; 193(3): 551-555, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32524584
19.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Br J Haematol
; 193(4): 750-760, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33650100
20.
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Br J Haematol
; 194(1): 132-139, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33822368